Colorectal Cancer | Specialty

The colorectal cancer condition center is a comprehensive resource for clinical news and expert insights on colorectal cancer. Read more at OncLive.

Dr Pietrantonio on Amivantamab With/Without Chemotherapy in Right-Sided RAS/BRAF Wild-Type mCRC

February 18th 2025

Filippo Pietrantonio, MD, discusses updated efficacy with amivantamab as monotherapy and in combination with chemotherapy in metastatic colorectal cancer.

The OncFive: Top Oncology Articles for the Week of 2/9

February 15th 2025

Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.

NCCN Updates ctDNA Stance in Colon, Rectal, and MCC Guidelines

February 12th 2025

The NCCN guidelines have been updated to specify the standing of ctDNA as a biomarker in colon and rectal cancer, as well as in MCC.

Sotorasib Plus Panitumumab Provides Effective Targeted Therapy Option in KRAS G12C+ mCRC

February 11th 2025

Marwan G. Fakih, MD, discusses the FDA approval of sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

Dr Yaeger on the Efficacy of Adagrasib/Cetuximab in KRAS G12C+ mCRC

February 10th 2025

Rona Yaeger, MD, details the efficacy of adagrasib/cetuximab in heavily pretreated patients with KRAS G12C–mutant mCRC.

The OncFive: Top Oncology Articles for the Week of 2/2

February 8th 2025

Encorafenib combination boosts survival in BRAF V600E+ mCRC, pertuzumab biosimilar BLA is under review for HER2+ breast cancer, and more from OncLive.

Cabozantinib Plus Nivolumab Demonstrates Disease Control in Refractory MSS mCRC

February 8th 2025

The combination of cabozantinib and nivolumab showed 16-week disease control in microsatellite stable colorectal cancer.

Dr Fakih on the FDA Approval of Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC

February 7th 2025

Marwan G. Fakih, MD, discusses the FDA approval of sotorasib plus panitumumab for adult patients with KRAS G12C–mutated metastatic colorectal cancer.

Envafolimab Plus Suvemcitug and FOLFIRI Shows Early Efficacy, Tolerability in Second-Line CRC

February 7th 2025

Envafolimab plus suvemcitug and FOLFIRI demonstrated preliminary activity and tolerability in second-line MSS/pMMR CRC.

Dr Fakih on Responses With Botensilimab Plus Balstilimab in MSS CRC

February 6th 2025

Marwan G. Fakih, MD, discusses response rates with botensilimab plus balstilimab in patients with microsatellite-stable colorectal cancer.

First results of nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability high/ mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW

February 6th 2025

Dr. Heinz-Josef Lenz presents first results from the CheckMate 8HW trial, demonstrating that nivolumab plus ipilimumab significantly improves progression-free survival and overall response rates compared to nivolumab monotherapy in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer across all lines of therapy.

OncLive’s FDA Approval Report: The Regulatory Rundown for January 2025

February 3rd 2025

Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.

Encorafenib/Cetuximab Plus Chemo Improves Survival in BRAF V600E+ mCRC

February 3rd 2025

Encorafenib plus cetuximab and mFOLFOX6 improved PFS and OS vs chemotherapy in BRAF V600E–mutant metastatic colorectal cancer.

Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC

February 3rd 2025

The combination of botensilimab plus balstilimab elicited high major pathologic response rates with extended time to surgery in resectable colorectal cancer.

Five Under 5: Top Oncology Videos for the Week of 1/26

February 2nd 2025

The top 5 videos of the week cover insights in gastrointestinal cancers, gynecologic malignancies, and blood cancers.

Dr Raghav on ABBV-400 Plus 5-FU, Folinic Acid, and Bevacizumab in Previously Treated mCRC

January 31st 2025

Kanwal PS Raghav, MBBS, MD, discusses ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated mCRC.

Dr Foote on the Ongoing Debate Over Upfront EGFR Inhibitor Use in CRC

January 30th 2025

Michael Foote, MD, discusses the use of EGFR inhibitors in the first vs subsequent lines of therapy for patients with metastatic colorectal cancer.

BRAF V600E-Mutant Metastatic CRC Confers Poor Survival Outcomes Regardless of Synchronous vs Metachronous Status

January 30th 2025

Patients with BRAF V600E-mutant metastatic colorectal cancer experience poor clinical outcomes, according to real-world data.

Dr André on Nivolumab Plus Ipilimumab in MSI-H/dMMR mCRC

January 29th 2025

Thierry André, MD, discusses the efficacy of nivolumab plus ipilimumab vs nivolumab monotherapy in MSI-H/dMMR mCRC.

Dr Shaukat on the PREEMPT CRC Blood-Based Assay for Average-Risk CRC

January 28th 2025

Aasma Shaukat, MD, MPH, discusses the sensitivity of the PREEMPT CRC blood-based assay in detecting colorectal cancer for patients at average risk.